Browse

The rejection may make the pharma firms remaining lawsuits more difficult.

The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…